This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Thrombocytopenia Treatment Market

Market Insights on Thrombocytopenia Treatment covering sales outlook, demand forecast & up-to-date key trends

Thrombocytopenia Treatment Market by Drug Class, Distribution Channel & Region | Forecast 2023 to 2033

Thrombocytopenia Treatment Market Snapshot (2023 to 2033)

During the projected period from 2023 to 2033, the global market for thrombocytopenia treatment is conjectured to surge at a CAGR of 5.2%. In 2033, the industry is forecasted to reach a valuation of US$ 10 Billion from US$ 6 Billion in 2023. Increased thrombocytopenia morbidity and mortality rates, inexpensive thrombocytopenia therapy, and rising knowledge of thrombocytopenia and its treatment are among the reasons driving the worldwide thrombocytopenia treatment market.

Blood clots are due to platelets in the blood. Thrombocytopenia is defined as an abnormally low platelet count in the blood due to the presence of any illness or ailment. Individuals with thrombocytopenia have delayed or no blood clotting. Because of the high prevalence of thrombocytopenia and growing knowledge of treatment alternatives, the worldwide thrombocytopenia treatment market is likely to grow considerably in the near future.

Thrombocytopenia symptoms include nosebleeds, bruises, redness, and bleeding in the gums and mouth. Thrombocytopenia is discovered using tests such as a complete blood count (CBC) and a blood clotting study. Furthermore, biopsy and bone marrow aspiration are used to diagnose thrombocytopenia. According to a study published in Professional Med J in 2014 titled Incidence of Thrombocytopenia, the prevalence of thrombocytopenia is greater in persons aged 60 years and older who had non-cirrhotic liver disease. However, rapid discovery, along with the capacity to clone thrombopoietin, has resulted in novel therapeutic worldwide treatment options.

Data Points

Key Statistics

Expected Market Value (2023)

US$ 6 Billion

Anticipated Forecast Value (2033)

US$ 10 Billion

Projected Growth Rate (2023 to 2033)

5.2% CAGR

Customize this Report

Let us know your requirement to get
100% FREE customization

Thrombocytopenia Treatment Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for thrombocytopenia treatment is projected to increase at a CAGR of 5.2% during the forecast period between 2023 and 2033, reaching a total of US$ 10 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 4%.

Due to the high prevalence of thrombocytopenia and increased knowledge about treatment alternatives, the worldwide thrombocytopenia treatment market is likely to grow considerably in the near future. Stringent regulatory clearances, on the other hand, and thrombocytopenia diagnostic delays are factors restricting the worldwide thrombocytopenia treatment market.

Which are Some Prominent Drivers of Thrombocytopenia Treatment Market?

The Approval of Efficient and Safe Medications for Thrombocytopenia Therapy will provide the Thrombocytopenia Treatment Industry with a Boost

Treatment approaches are generally tailored to the underlying cause of thrombocytopenia. The underlying reason for thrombocytopenia is not always understood, especially in situations of severe bleeding. Shionogi Inc.'s Lusutrombopag, an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist, was approved by Japan's Pharmaceuticals and Medical Devices Agency in September 2015.

Lusutrombopag improved chronic liver disease (CLD) linked with thrombocytopenia in individuals undergoing invasive operations. Lusustrombopag operates exclusively on human thrombopoietin (TPO) receptors, stimulating signaling pathways that cause bone marrow cells to proliferate and differentiate into megakaryocytes. As a result, the blood platelet count rises. Patients using Lusustrombopag, on the other hand, had greater blood leukocyte and erythrocyte counts.

Furthermore, Rigel Pharmaceuticals, Inc. submitted an application to the FDA in June 2017 for a new oral experimental medication, Tavalisse (fostamatinib disodium). This medication is intended to treat individuals with chronic or persistent immune thrombocytopenia by inhibiting the spleen tyrosine kinase.

Another Novartis medicine, Eltrombopag, an oral, non-peptide thrombopoietin receptor agonist, has proven effectiveness and safety in individuals with persistent immune thrombocytopenia (CIT). This medication is licensed in the United States and registered in Europe. Eltrombopag at low dosage is effective and safe for CIT prevention. Long-term use of thrombopoietin (TPO) receptor agonists is safe for patients with chronic lymphocytic leukemia accompanied by immune thrombocytopenia, according to Case Reports Hematology, because they are non-immunosuppressive medications.

Growing Prevalence of Thrombocytopenia to Accelerate Market Growth

The global incidence of thrombocytopenia is driving the thrombocytopenia therapy market. Chronic Hepatitis C patients are at a substantially increased risk of developing thrombocytopenia. According to the World Health Organization (WHO), the prevalence of Hepatitis C was lower in the Americas and Europe in 2014 compared to Africa and Pakistan, where the incidence of chronic liver disease was 4-6% higher. Liver disease has emerged as a socioeconomic and worldwide health issue, affecting 60-80% of the population.

Furthermore, rising government support for fast-track approval in order to discover newer treatments for this disorder, as well as capital investments in the creation of new drugs by biotechnology and pharmaceutical companies, are expected to drive growth in the thrombocytopenia treatment market over the coming years.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which are the Trough Areas faced by the Thrombocytopenia Treatment Market?

Patent Expiration is a Key Obstacle, Stifling the Market Growth

The thrombocytopenia treatment market is predicted to slow considerably in 2023 due to patent expiry and the rising availability of generic Promacta and MabThera.

Region-wise Insights

How will Thrombocytopenia Treatment Market Demand progress in the Asia Pacific?

Rapidly Increasing Medical Tourism Business in Asia Pacific Widening Profit Margins

The Asia Pacific region is a particularly appealing market for thrombocytopenia treatment. Factors such as the rapidly increasing medical tourism business in Asia Pacific, particularly in India and China, are likely to draw patients from all over the world for treatment. The presence of a large patient pool in the Asia Pacific is likely to raise the risk of morbidity associated with thrombocytopenia in the area.

Furthermore, initiatives taken by governments in Asia Pacific countries to promote the healthcare sector in these countries benefits from foreign currency differences, and the availability of skilled and qualified workforce are among the factors expected to attract global players to the Asia Pacific thrombocytopenia treatment market in the near future. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 4.9% in the assessment period 2023 to 2033.

How attractive are Growth Prospects for Thrombocytopenia Treatment in North America?

Strong Lab Infrastructure and Fast Expanding Research in Anticoagulant Medicines

North America has seen significant revenue opportunities as a result of strong lab infrastructure and fast-expanding research in anticoagulant medicines. Pathophysiology has also benefited the area's healthcare system.

Growing public knowledge of the morbidity and mortality associated with heparin treatment in patients, particularly in heart surgery operating rooms, has hampered research in nations such as the United States. North America is expected to grow at a CAGR of 5.1% in the assessment period 2023 to 2033.

What Factors favoring the Growth of Thrombocytopenia Treatment in Europe?

Favorable Reimbursement Policies fuelling sales of Thrombocytopenia Treatment

Europe is the second leading market in thrombocytopenia treatments. The morbidity rate caused by thrombocytopenia is high in affluent nations, whereas the fatality rate is high in poor countries.

Favorable reimbursement policies, high healthcare spending, a well-structured regulatory framework, a high rate of compliance with defined regulations, the availability of highly advanced healthcare facilities, and high awareness of thrombocytopenia and its treatment are some of the factors propelling the thrombocytopenia treatment market in Europe. Thus, owing to the aforementioned reasons, the region is expected to grow at a CAGR of 5% in the assessment period 2023 to 2033.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category-wise Insights

Which is the Most Preferred Drug Class Segment?

The Glucocorticoids Segment to enhance Sales Prospects

On the basis of drug class, the thrombocytopenia treatment market is segmented into glucocorticoids, lysosomal enzymes, and platelet-stimulating agents. Glucocorticoids are expected to hold the largest share of the market.

Glucocorticoids are the usual first-line therapy for people with immune thrombocytopenic purpura (ITP) because of their efficacy in boosting platelet count, cheap cost, and ease of administration.

Which is the Most Popular Distribution Channel in the Thrombocytopenia Treatment Market?

The Hospital Pharmacies Segment to Drive the Market Growth

On the basis of distribution channels, the thrombocytopenia treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to hold the lion’s share in the market due to their low price and easy availability.

On the other hand, the online pharmacies segment is likely to gain momentum during the forecast period, due to hefty discounts amid the soaring e-commerce sector.

Start-ups offering Thrombocytopenia Treatment

Key start-up players in the thrombocytopenia treatment are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. One of the key thrombocytopenia treatment start-ups is as follows:

  • Sexton Biotechnologies is a firm headquartered in the United States that creates human platelet lysate products. Pathogen-free human platelet lysates (GPL) are a medium that lowers risks and increases downstream performance when compared to alternatives. Signata, the startup's gene therapy platform, uses closed automation to limit contamination concerns, gather batch records, and regulate operations with a flexible system.

Market Competition

The thrombocytopenia treatment industry has experienced potential clinical breakthroughs as a result of ongoing guidelines changes. The 2018 American Society of Hematology (ASH) Guideline recommended a variety of alternative anticoagulant alternatives for doctors to consider.

Current practice recommendations in industrialized countries have prompted the development of novel thrombin inhibitors and immunoassays. This has increased therapy possibilities for acute thrombocytopenia treatment. Top players intend to introduce new anticoagulants to improve healthcare team outcomes. Manufacturers of assays and pharmaceuticals are focusing on lowering the probability of thromboembolic consequences.

Key players in the thrombocytopenia treatment market are 3SBio Inc., Amgen Inc., Takeda Pharmaceutical Company, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai Co., Ltd., Hansa Medical AB, Intas Pharmaceuticals Ltd. and Merck & Co., Inc.

Recent Developments:

  • In December 2021, Horizon Therapeutics Plc's board of directors and Amgen Inc.'s board of directors announced that they have agreed on the terms of a cash offer for the Company by Pillartree Limited (Acquirer Sub), a newly formed private limited company wholly owned by Amgen, which is unanimously recommended by the Company Board and pursuant to which Acquirer Sub will acquire the entire issued and to be issued
  • In December 2020, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., a subsidiary of 3SBio Inc., and Verseau Therapeutics, Inc. announced the selection of a monoclonal antibody targeting VSIG4 as a license program under their partnership arrangement aimed at the creation and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a variety of cancers.

Report Scope

Report Attribute

Details

Market Value in 2023

US$ 6 Billion

Market Value in 2033

US$ 10 Billion

Growth Rate

CAGR of 5.2% from 2023 to 2033

Base Year for Estimation

2022

Historical Data

2018 to 2022

Forecast Period

2023 to 2033

Quantitative Units

Revenue in US Billion and CAGR from 2023 to 2033

Report Coverage

Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis

Segments Covered

  • Drug Class
  • Distribution Channel
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Key Countries Profiled

  • The USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Singapore
  • Thailand
  • Indonesia
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel

Key Companies Profiled

  • 3SBio Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Company
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Hansa Medical AB
  • Intas Pharmaceuticals Ltd.
  • Merck & Co. Inc.

Customization

Available Upon Request

Key Segments Profiled in the Thrombocytopenia Treatment Industry Survey

By Drug Class:

  • Glucocorticoids
  • Lysosomal Enzyme
  • Platelet Stimulating Agent

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

FMI projects the global thrombocytopenia treatment market to expand at a 5.2% value CAGR by 2033

The global thrombocytopenia treatment market is estimated at a market value of US$ 6 Billion

The global thrombocytopenia treatment market is expected to garner a market value of US$ 10 Billion

Asia Pacific to be the most lucrative for thrombocytopenia treatment market growth.

3SBio Inc., Amgen Inc., Takeda Pharmaceutical Company, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai Co., Ltd., Hansa Medical AB, Intas Pharmaceuticals Ltd. and Merck & Co., Inc are some prominent thrombocytopenia treatment market players.

North America is expected to grow at a CAGR of 5.1% in the assessment period 2023 to 2033.

Europe is expected to grow at a CAGR of 5% in the assessment period 2023 to 2033.

The glucocorticoids segment is expected to hold the largest market share for thrombocytopenia treatment in the forecast period 2023 to 2033.

Table of Content

1. Executive Summary | Thrombocytopenia Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Glucocorticoids

        5.3.2. Lysosomal Enzyme

        5.3.3. Platelet Stimulating Agent

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        6.3.1. Hospital Pharmacies

        6.3.2. Retail Pharmacies

        6.3.3. Online Pharmacies

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. Middle East and Africa (MEA)

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. The USA

            8.2.1.2. Canada

        8.2.2. By Drug Class

        8.2.3. By Distribution Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Class

        8.3.3. By Distribution Channel

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Class

        9.2.3. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Distribution Channel

    9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. The United Kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Drug Class

        10.2.3. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Distribution Channel

    10.4. Key Takeaways

11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. Singapore

            11.2.1.5. Thailand

            11.2.1.6. Indonesia

            11.2.1.7. Australia

            11.2.1.8. New Zealand

            11.2.1.9. Rest of Asia Pacific

        11.2.2. By Drug Class

        11.2.3. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Distribution Channel

    11.4. Key Takeaways

12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of MEA

        12.2.2. By Drug Class

        12.2.3. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Distribution Channel

    12.4. Key Takeaways

13. Key Countries Market Analysis

    13.1. The USA

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2022

            13.1.2.1. By Drug Class

            13.1.2.2. By Distribution Channel

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2022

            13.2.2.1. By Drug Class

            13.2.2.2. By Distribution Channel

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2022

            13.3.2.1. By Drug Class

            13.3.2.2. By Distribution Channel

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2022

            13.4.2.1. By Drug Class

            13.4.2.2. By Distribution Channel

    13.5. Germany

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2022

            13.5.2.1. By Drug Class

            13.5.2.2. By Distribution Channel

    13.6. The United Kingdom

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2022

            13.6.2.1. By Drug Class

            13.6.2.2. By Distribution Channel

    13.7. France

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2022

            13.7.2.1. By Drug Class

            13.7.2.2. By Distribution Channel

    13.8. Spain

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2022

            13.8.2.1. By Drug Class

            13.8.2.2. By Distribution Channel

    13.9. Italy

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2022

            13.9.2.1. By Drug Class

            13.9.2.2. By Distribution Channel

    13.10. China

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2022

            13.10.2.1. By Drug Class

            13.10.2.2. By Distribution Channel

    13.11. Japan

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2022

            13.11.2.1. By Drug Class

            13.11.2.2. By Distribution Channel

    13.12. South Korea

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2022

            13.12.2.1. By Drug Class

            13.12.2.2. By Distribution Channel

    13.13. Singapore

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2022

            13.13.2.1. By Drug Class

            13.13.2.2. By Distribution Channel

    13.14. Thailand

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2022

            13.14.2.1. By Drug Class

            13.14.2.2. By Distribution Channel

    13.15. Indonesia

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2022

            13.15.2.1. By Drug Class

            13.15.2.2. By Distribution Channel

    13.16. Australia

        13.16.1. Pricing Analysis

        13.16.2. Market Share Analysis, 2022

            13.16.2.1. By Drug Class

            13.16.2.2. By Distribution Channel

    13.17. New Zealand

        13.17.1. Pricing Analysis

        13.17.2. Market Share Analysis, 2022

            13.17.2.1. By Drug Class

            13.17.2.2. By Distribution Channel

    13.18. GCC Countries

        13.18.1. Pricing Analysis

        13.18.2. Market Share Analysis, 2022

            13.18.2.1. By Drug Class

            13.18.2.2. By Distribution Channel

    13.19. South Africa

        13.19.1. Pricing Analysis

        13.19.2. Market Share Analysis, 2022

            13.19.2.1. By Drug Class

            13.19.2.2. By Distribution Channel

    13.20. Israel

        13.20.1. Pricing Analysis

        13.20.2. Market Share Analysis, 2022

            13.20.2.1. By Drug Class

            13.20.2.2. By Distribution Channel

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Drug Class

        14.3.3. By Distribution Channel

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. 3SBio Inc.

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. Amgen Inc.

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. Takeda Pharmaceutical Company

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. Bayer AG

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Boehringer Ingelheim GmbH

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. Bristol-Myers Squibb Company

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. Eisai Co., Ltd.

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. Hansa Medical AB

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. Intas Pharmaceuticals Ltd.

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. Merck & Co. Inc.

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ million) Forecast by Drug Class, 2018 to 2033

Table 3: Global Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 4: North America Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ million) Forecast by Drug Class, 2018 to 2033

Table 6: North America Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 7: Latin America Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ million) Forecast by Drug Class, 2018 to 2033

Table 9: Latin America Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 10: Europe Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ million) Forecast by Drug Class, 2018 to 2033

Table 12: Europe Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 13: Asia Pacific Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 14: Asia Pacific Market Value (US$ million) Forecast by Drug Class, 2018 to 2033

Table 15: Asia Pacific Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 16: MEA Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 17: MEA Market Value (US$ million) Forecast by Drug Class, 2018 to 2033

Table 18: MEA Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ million) by Drug Class, 2023 to 2033

Figure 2: Global Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 3: Global Market Value (US$ million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ million) Analysis by Drug Class, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 10: Global Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 13: Global Market Attractiveness by Drug Class, 2023 to 2033

Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ million) by Drug Class, 2023 to 2033

Figure 17: North America Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 18: North America Market Value (US$ million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ million) Analysis by Drug Class, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 25: North America Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 28: North America Market Attractiveness by Drug Class, 2023 to 2033

Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ million) by Drug Class, 2023 to 2033

Figure 32: Latin America Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 33: Latin America Market Value (US$ million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ million) Analysis by Drug Class, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 40: Latin America Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Drug Class, 2023 to 2033

Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ million) by Drug Class, 2023 to 2033

Figure 47: Europe Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 48: Europe Market Value (US$ million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ million) Analysis by Drug Class, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 55: Europe Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 58: Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: Asia Pacific Market Value (US$ million) by Drug Class, 2023 to 2033

Figure 62: Asia Pacific Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 63: Asia Pacific Market Value (US$ million) by Country, 2023 to 2033

Figure 64: Asia Pacific Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: Asia Pacific Market Value (US$ million) Analysis by Drug Class, 2018 to 2033

Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 70: Asia Pacific Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 73: Asia Pacific Market Attractiveness by Drug Class, 2023 to 2033

Figure 74: Asia Pacific Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 76: MEA Market Value (US$ million) by Drug Class, 2023 to 2033

Figure 77: MEA Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 78: MEA Market Value (US$ million) by Country, 2023 to 2033

Figure 79: MEA Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: MEA Market Value (US$ million) Analysis by Drug Class, 2018 to 2033

Figure 83: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 84: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 85: MEA Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 86: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 87: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 88: MEA Market Attractiveness by Drug Class, 2023 to 2033

Figure 89: MEA Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 90: MEA Market Attractiveness by Country, 2023 to 2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Heparin-Induced Thrombocytopenia (HIT) Treatment Market

Published : January 2020

Healthcare

Thrombophilia Testing Market

Published : August 2019

Healthcare

Antithrombotic Drugs Market

Published : March 2017

Healthcare

Idiopathic Thrombocytopenic Purpura Therapeutics Market

Published : December 2016

Google translate

Thrombocytopenia Treatment Market